$Recro制药(REPH)$ 内部交易: 2021-11-12,CEO,ENLOE J DAVID JR ,买入,1725普通股, $1.68
$Recro制药(REPH)$ 内部交易: 2021-11-12,CFO,Lake Ryan David ,买入,1212普通股, $1.65
$Recro制药(REPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-044709 Size: 4 KB 网页链接
$Recro制药(REPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-044710 Size: 5 KB 网页链接
$Recro制药(REPH)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0000950170-21-004225 Act: 34 Size: 2 MB 网页链接
$Recro制药(REPH)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-21-003751 Act: 34 Size: 9 MB 网页链接
$Recro制药(REPH)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-21-003741 Act: 34 Size: 641 KB 网页链接
$Recro制药(REPH)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-21-270098 Act: 33 Size: 258 KB 网页链接
$Recro制药(REPH)$ 8-K/A [Amend] Current report, items 8.01 and 9.01 Accession Number: 0000950170-21-001765 Act: 34 Size: 1 MB 网页链接
$Recro制药(REPH)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0000950170-21-001537 Act: 34 Size: 2 MB 网页链接